logo

Fulcrum Therapeutics (FULC)



Trade FULC now with
  Date
  Headline
8/2/2022 8:48:06 AM Fulcrum Therapeutics® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
6/10/2022 7:18:37 AM Fulcrum Therapeutics Announces Proof-of-Concept For FTX-6058 In Sickle Cell Disease Based On Phase 1b Initial Data
9/10/2021 7:32:08 AM Fulcrum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
8/10/2021 9:21:45 AM Fulcrum Announces Positive Interim Results From Phase 1 Healthy Volunteer Trial Of FTX-6058 For Sickle Cell Disease
1/19/2021 11:23:23 PM Fulcrum Therapeutics Prices Public Offering Of 4 Mln Shares At $11/Shr For Total Gross Proceeds Of $44.0 Mln